Alternative Sunitinib Scheduling for mRCC

March 28, 2017
Eric Jonasch, MD

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).